Clinical Trials · NCT00612794
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 30
- Start date
- Sep 2007
- Locations
- 4 sites, Japan
- Primary endpoint
- To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus.